1. Home
  2. CVKD vs EONR.WS Comparison

CVKD vs EONR.WS Comparison

Compare CVKD & EONR.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

EONR.WS

EON Resources Inc. Warrants each whole warrant exercisable for three quarters of one share of Class A Common Stock at an exercise price of $11.50 per whole share

N/A

Current Price

$0.04

Market Cap

2.8M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
EONR.WS
Founded
2022
N/A
Country
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CVKD
EONR.WS
Price
$1.71
$0.04
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $14.00
N/A
AVG Volume (30 Days)
★ 103.3K
320.0
Earning Date
11-16-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 23.94
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.07
52 Week High
$12.50
$0.07

Technical Indicators

Market Signals
Indicator
CVKD
EONR.WS
Relative Strength Index (RSI) 66.44 N/A
Support Level $0.88 N/A
Resistance Level $2.23 N/A
Average True Range (ATR) 0.21 0.00
MACD 0.07 0.00
Stochastic Oscillator 78.44 0.00

Price Performance

Historical Comparison
CVKD
EONR.WS

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: